331 related articles for article (PubMed ID: 34571054)
1. American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer.
Amini A; Verma V; Simone CB; Chetty IJ; Chun SG; Donington J; Edelman MJ; Higgins KA; Kestin LL; Movsas B; Rodrigues GB; Rosenzweig KE; Rybkin II; Slotman BJ; Wolf A; Chang JY
Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):361-375. PubMed ID: 34571054
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline.
Iyengar P; All S; Berry MF; Boike TP; Bradfield L; Dingemans AC; Feldman J; Gomez DR; Hesketh PJ; Jabbour SK; Jeter M; Josipovic M; Lievens Y; McDonald F; Perez BA; Ricardi U; Ruffini E; De Ruysscher D; Saeed H; Schneider BJ; Senan S; Widder J; Guckenberger M
Pract Radiat Oncol; 2023; 13(5):393-412. PubMed ID: 37294262
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic radiotherapy in oligometastatic cancer.
Kennedy TAC; Corkum MT; Louie AV
Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S16. PubMed ID: 28917254
[TBL] [Abstract][Full Text] [Related]
4. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
Hasan H; Deek MP; Phillips R; Hobbs RF; Malek R; Radwan N; Kiess AP; Dipasquale S; Huang J; Caldwell T; Leitzel J; Wendler D; Wang H; Thompson E; Powell J; Dudley S; Deville C; Greco SC; Song DY; DeWeese TL; Gorin MA; Rowe SP; Denmeade S; Markowski M; Antonarakis ES; Carducci MA; Eisenberger MA; Pomper MG; Pienta KJ; Paller CJ; Tran PT
BMC Cancer; 2020 Jun; 20(1):492. PubMed ID: 32487038
[TBL] [Abstract][Full Text] [Related]
5. Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy.
Dohopolski M; Iyengar P
Ann Palliat Med; 2021 May; 10(5):5944-5953. PubMed ID: 33691460
[TBL] [Abstract][Full Text] [Related]
6. Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer.
Doyle E; Killean AJ; Harrow S; Phillips ID
Radiother Oncol; 2024 Jul; 196():110288. PubMed ID: 38648995
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic ablative body radiation for oligometastatic and oligoprogressive disease.
Ning MS; Gomez DR; Heymach JV; Swisher SG
Transl Lung Cancer Res; 2019 Feb; 8(1):97-106. PubMed ID: 30788239
[TBL] [Abstract][Full Text] [Related]
8. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
[TBL] [Abstract][Full Text] [Related]
9. Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.
Hannan R; Christensen M; Hammers H; Christie A; Paulman B; Lin D; Garant A; Arafat W; Courtney K; Bowman I; Cole S; Sher D; Ahn C; Choy H; Timmerman R; Brugarolas J
Eur Urol Oncol; 2022 Apr; 5(2):216-224. PubMed ID: 34986993
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
[TBL] [Abstract][Full Text] [Related]
11. Role of radiation in oligometastases and oligoprogression in metastatic non-small cell lung cancer: consensus and controversy.
Kumar A; Salama JK
Expert Rev Respir Med; 2023; 17(11):1033-1040. PubMed ID: 37962878
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of oligometastatic or oligoprogression cancer].
Bourgier C; Latorzeff I; Fenoglietto P; Boisselier P; Charissoux M; Llacer C; Lemanski C; Riou O; Farcy-Jacquet MP; Azria D
Cancer Radiother; 2019 Oct; 23(6-7):482-485. PubMed ID: 31495737
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiation therapy (SBRT) for patients with oligometastatic/oligoprogressive adrenal metastases: Outcomes and toxicities profile in a monoinstitutional study.
Facondo G; Vullo G; Valeriani M; Ascolese AM; De Sanctis V; Osti MF
Cancer Treat Res Commun; 2021; 29():100481. PubMed ID: 34700142
[TBL] [Abstract][Full Text] [Related]
14. A Contemporary Update on the Role of Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases in the Evolving Landscape of Oligometastatic Disease Management.
Robin TP; Raben D; Schefter TE
Semin Radiat Oncol; 2018 Oct; 28(4):288-294. PubMed ID: 30309639
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiation therapy for oligometastatic gynecologic malignancies: A systematic review.
Yegya-Raman N; Cao CD; Hathout L; Girda E; Richard SD; Rosenblum NG; Taunk NK; Jabbour SK
Gynecol Oncol; 2020 Nov; 159(2):573-580. PubMed ID: 32917412
[TBL] [Abstract][Full Text] [Related]
16. The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review.
Le Guevelou J; Sargos P; Siva S; Ploussard G; Ost P; Gillessen S; Zilli T
Eur Urol Focus; 2023 Jan; 9(1):114-124. PubMed ID: 36151031
[TBL] [Abstract][Full Text] [Related]
17. Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer.
Franzese C; Badalamenti M; Teriaca A; De Virgilio A; Mercante G; Cavina R; Ferrari D; Santoro A; Spriano G; Scorsetti M
J Cancer Res Clin Oncol; 2021 May; 147(5):1307-1313. PubMed ID: 33471186
[TBL] [Abstract][Full Text] [Related]
18. Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma.
Raj RK; Upadhyay R; Wang SJ; Singer EA; Dason S
Curr Oncol; 2023 Dec; 30(12):10283-10298. PubMed ID: 38132383
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
Collen C; Christian N; Schallier D; Meysman M; Duchateau M; Storme G; De Ridder M
Ann Oncol; 2014 Oct; 25(10):1954-1959. PubMed ID: 25114022
[TBL] [Abstract][Full Text] [Related]
20. Changing equipoise in the landscape of radiation for oligometastatic lung cancer.
Schroeder SR; Leenders M; Iyengar P; de Ruysscher D
Transl Lung Cancer Res; 2019 Sep; 8(Suppl 2):S184-S191. PubMed ID: 31673523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
